Trump signs executive order imposing 100% tariff on some pharmaceutical drugs
The order targets imported branded pharmaceuticals, escalating trade pressure on drugmakers with global supply chains.
Supply Chain Dive · +13 outlets
GRAIL shares jump 12.9% after FDA panel gives positive verdict on Galleri trial results
The advisory panel's backing moves GRAIL's multi-cancer early detection blood test closer to a US regulatory decision.
Yahoo Finance · +4 outlets
Pfizer halts development of closely watched weight-loss drug
Pfizer's exit from an obesity candidate narrows its GLP-1 ambitions as competition in the market intensifies.
polskieradio.pl · +6 outlets
Capricor faces make-or-break FDA panel on deramiocel Duchenne cell therapy
The advisory meeting is pivotal for Capricor's lead cell therapy after an analyst cut the stock's price target by 86%.
Stocktwits · +3 outlets
Novo Nordisk says obesity drug trial confirms weight loss as pipeline wins meet a tough market
Fresh trial confirmation supports Novo's obesity franchise even as its shares struggle to find a floor amid GLP-1 competition.
BusinessWorld Online · +14 outlets
Weight-loss drug forecasts jump to $150B as supply grows and price war arrives
Expanding manufacturing capacity and new discounting are reshaping the economics of the GLP-1 market.
polskieradio.pl · +3 outlets
South Korea's KOSDAQ pharma index plunges 10% in a month, down 36% year to date
The selloff reflects waning investor appetite for Korean biotech after a prolonged run-up in obesity and pipeline hopes.
finance.biggo.com · +1 outlets
Eli Lilly gains FDA approval for Jaypirca
The approval expands Lilly's oncology portfolio beyond its dominant metabolic franchise.
Mugglehead Investment Magazine · +14 outlets
Moleculin Biotech shares drop 25% as interim cancer trial data falls short of significance
The interim readout weakens confidence in the company's lead oncology asset ahead of fuller data disclosure.
Stocktwits · +3 outlets
Psilocybin, LSD and other psychedelics move toward FDA approval
Regulatory momentum for psychedelic-assisted therapies is building despite unresolved trial-design and safety questions.
Psychology Today · +14 outlets
FDA extends review of Novo Nordisk's denecimig over facility remediation
The delay ties a hemophilia candidate's timeline to manufacturing quality fixes at a Novo facility.
Mugglehead Investment Magazine · +10 outlets
Genmab reports 45.9% Rina-S response rate in ovarian cancer trial
The response rate supports continued development of the antibody-drug conjugate in gynecologic cancers.
Mugglehead Investment Magazine · +2 outlets
Fate Therapeutics shares jump 6% as FDA clears cell therapy to enter clinical trials
The IND clearance advances the company's iPSC-derived cell therapy into human testing.
Stocktwits · +1 outlets
Medtronic reports 88.1% ulcer healing in two-year VenaSeal study
The longer-term data supports the company's venous closure device in treating leg ulcers.
Mugglehead Investment Magazine
Pyxis Oncology to present updated Phase 1 data for micvotabart pelidotin
The data update comes as the company cites a better cash runway for the remaining MICVO development program.
scanx.trade · +9 outlets
Replimune's melanoma FDA decision pending as analyst sees 40% upside and high conviction on approval
The upcoming decision is a key catalyst for Replimune's oncolytic immunotherapy franchise.
Stocktwits · +2 outlets
NovoCure breaks out on Q2 2026 earnings as Optune Pax drives recovery
The quarterly results signal improving adoption of the company's tumor treating fields platform.
TradingKey · +1 outlets
FDA approval of rusfertide redefines polycythemia vera treatment paradigm
The approval gives patients with the rare blood cancer a new first-in-class option.
Targeted Oncology · +1 outlets